Activation of the NLRP3 inflammasome in response to danger signals is a key innate immune mechanism and results in the production of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) as well as pyroptotic cell death. NLRP3 is the crucial molecular sensor that recognizes a wide range of danger signals and aberrant NLRP3 activation has been linked to many acute and chronic conditions ranging from atherosclerosis to Alzheimer’s disease and cancer. Based on the clinical success of IL-1-targeting therapies, NLRP3 has emerged as an attractive therapeutic target
Over the past decade, the NLRP3 field has evolved from target discovery to having several compounds in clinical studies. This webinar will discuss the NLRP3 drug discovery program at Novartis, from phenotypic pathway inhibitors to understanding the targeting of the protein itself. This enabled the creation of a broad medicinal chemistry program starting from a high-throughput screen. Given the extensive indication potential for NLRP3 inhibitors to act in both peripheral and central compartments, specific optimization strategies are necessary to maximize the therapeutic potential of this most promising target.
Join us for an exciting webinar on targeted compound design!
